Compare Lumen Technologies Inc (LUMN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Lumen Technologies Inc trades at $6.41 (market cap $6.58B), while Regeneron Pharmaceuticals Inc trades at $793.81 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 12.5× Lumen Technologies Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals.
| LUMN | REGN | |
|---|---|---|
Market Cap | $6.58B | $82.06B |
Sector | Media | Health |
52-Week High | $11.83 | $812.27 |
52-Week Low | $3.95 | $555.51 |
Enterprise Value | $18.20B | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN stock trades at $6.64, up 6.41% on the day, with a neutral technical stance. Recent Q2 2026 earnings beat estimates despite a 9.3% revenue decline, as strategic revenues grew 14.1%. The company maintains a high debt load of $17.49 billion, but operating cash flow remains strong at $4.74 billion for 2025. CEO share purchases and board appointments signal internal confidence amid a challenging transformation.
The outlook is cautious; while digital transformation shows progress, persistent revenue declines and negative net income margins pose significant risks. Analyst consensus is a Hold with a $7.67 price target, reflecting skepticism about near-term profitability. High debt and legacy business erosion remain key concerns for investors.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
